The Alzheimer’s Research UK Oxford Drug Discovery Institute (ODDI) couples the deep disease knowledge and biology expertise of the academic community with high quality, innovative drug discovery technologies. This initiative is based on juxtaposing high quality drug discovery expertise alongside a deep scientific and academic understanding of patients, disease mechanisms, and model systems. The intent is to translate cutting edge academic science into drug discovery, and to prosecute projects from target to lead status, and beyond.
Housed within The Target Discovery Institute at the University of Oxford, the ODDI is uniting collaborative efforts for target identification with sophisticated target development capabilities. Led by the CSO, Dr John Davis, the ODDI focuses on novel targets in the dementia therapeutic area, bringing together researchers from Biology, Chemistry, Psychiatry, and Neuroscience. The institute is part of a newly formed, world-class, network of three drug discovery institutes, sponsored by Alzheimer’s Research UK.
The Oxford Drug Discovery Institute is one of three Institutes within the Alzheimer’s Research UK Drug Discovery Alliance, working alongside Institutes at the University of Cambridge and University College London. The Alliance will accelerate the discovery of novel, effective therapeutics for Alzheimer’s disease and other neurodegenerative diseases.
Alzheimer’s Research UK unites more than 1000 dementia researchers from across the UK to support and streamline dementia research. The charity is dedicated to funding the best minds and forging the most effective partnerships to nurture discovery and ideas, as well as translating findings from this pioneering research into benefits for people with dementia. For more information, visit ARUK’s website.
@GraceGregory_ tweeted, "It's official... I am jumping out of a plane to raise money for Alzheimer's Research UK! https://justgiving.com/fundraising/gracegregory As a Research Assistant at the ARUK Oxford Drug Discovery Institute, I see exactly how vital fundraising is used in developing new drugs for Alzheimer's Disease. That's why I am taking part in the ARUK skydive as part of Alzheimer's Awareness Month on the 26th September 2021. My goal is £400. If you would like to support Alzheimer's Research UK and help me reach my target, please go to my ARUK JustGiving page." (link above)
Good luck Grace!
The John Black Senior Research Fellowship aims to build on the strengths of the University's Central Nervous System (CNS) research programmes and world leading research into the discovery and translation of novel therapeutic approaches for neurodegenerative diseases, with a particular focus on Parkinson's disease. As a principal investigator, Dr Milosevic will provide strategic and academic leadership, pioneering studies and development of ...
On Friday, 5th July, Alzheimer’s Research UK President, the Rt Hon David Cameron, visited the Oxford Drug Discovery Institute. This was a great opportunity for Mr Cameron to meet the ODDI team and hear first-hand about their drug discovery research. A number of senior representatives from the University of Oxford also came along to discuss the wider neuroscience agenda in Oxford. Mr Cameron really enjoyed the visit and went away feeling ...